The Food and Drug Administration’s top vaccine advisory committee has unanimously recommended Moderna’s new mRNA influenza vaccine, named mFlusiva, specifically for adults aged 50 and over. This represents the committee’s first review of a new vaccine application since 2023, marking a significant moment in the ongoing pandemic response.
The vote by the Vaccines and Related Biological Products Advisory Committee (VRBPAC) comes amid a backdrop of political contention surrounding vaccines. This could potentially lead to the first vaccine approval during the second Trump administration, despite previous criticisms from key figures such as President Trump and Health and Human Services Secretary Robert F. Kennedy Jr. Notably, last year, Kennedy had retracted nearly $500 million in funding intended for the development of mRNA vaccines. Dr. Paul Offit, director of the Vaccine Education Center at the Children’s Hospital of Philadelphia, expressed relief, stating, “It’s such a breath of fresh air, considering what we’ve gone through with Robert F. Kennedy Jr.”
Moderna’s mRNA influenza vaccine employs technology similar to that used in its COVID-19 vaccine. After a brief delay earlier this year, in which the FDA initially declined to review Moderna’s application, the agency reversed its decision following public outcry. The mRNA technology works by instructing the body to produce flu antigens that help build immunity. The vaccine is designed to contain microscopic doses of mRNA targeting three to four flu strains. This incredibly small amount is likened to the weight left by a fingerprint on a mirror.
Public health experts are optimistic about mRNA vaccines, believing they can be manufactured more rapidly and reliably than traditional flu vaccines. This speed may allow for more effective responses to newly emerging flu strains. During the latest review, both Moderna and the FDA reported that they did not identify credible safety concerns, with Moderna assuring that the vaccine does not interact with human DNA.
Research outcomes from Moderna’s phase 3 trial highlighted in prestigious medical journals suggest that the mRNA flu vaccine could elicit a longer-lasting immune response compared to current options. Dr. Anna Durbin, director of the Center for Immunization Research at Johns Hopkins University, affirmed that there were no shortcuts in the evaluation process and that extensive efficacy studies involving tens of thousands of participants were conducted.
Former FDA officials have pointed out the politicization of mRNA vaccines, dismissing claims that they pose a risk of causing cancer or affecting cellular DNA as unfounded. Dr. Jesse Goodman emphasized the importance of addressing misinformation, stating that public confidence will likely improve as evidence emerges.
The review conducted by the VRBPAC highlighted significant flu data—a staggering 32 million flu cases, 390,000 hospitalizations, and 24,000 deaths were recorded in the U.S. during the 2025-2026 flu season, with approximately 85% of those eligible for vaccination remaining unprotected. Dr. Evan Anderson, epidemiology vice president at Moderna, discussed the potential reduction in time needed to create targeted vaccines for specific flu strains, emphasizing the benefits of the mRNA platform.
Following extensive discussions, the committee’s nine members ultimately recommended mFlusiva, concluding that it may offer greater efficacy than traditional flu vaccines in preventing severe influenza-related illnesses. The committee met for over six hours before casting their unanimous vote.
Dr. Durbin praised the robust nature of the meeting and the transparency involved in the discussions. Observers have expressed concern regarding the overall functioning of the FDA and its advisory committees under the current administration, noting that the VRBPAC has not met frequently enough in recent years.
If the new vaccine receives the necessary approvals, Moderna has indicated that it could be available for the upcoming flu season. The situation remains dynamic, with stakeholders advocating for the continual engagement of expert advisory committees to ensure comprehensive reviews of new vaccines.
